Micardis Hct Tablet
NDC Package 0597-0044-37
Package Information
Micardis Hct (telmisartan and hydrochlorothiazide) tablets is a medication used to treat high blood pressure (hypertension). This formulation utilizes a tablet delivery system. Marketed by Boehringer Ingelheim Pharmaceuticals, Inc., this product is identified by NDC 0597-0044 and is authorized under FDA application NDA021162.
Identification & Billing
- RxCUI: 283316 - telmisartan 40 MG / hydroCHLOROthiazide 12.5 MG Oral Tablet
- RxCUI: 283316 - hydrochlorothiazide 12.5 MG / telmisartan 40 MG Oral Tablet
- RxCUI: 283316 - HCTZ 12.5 MG / telmisartan 40 MG Oral Tablet
- RxCUI: 283317 - telmisartan 80 MG / hydroCHLOROthiazide 12.5 MG Oral Tablet
- RxCUI: 283317 - hydrochlorothiazide 12.5 MG / telmisartan 80 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0597 - Boehringer Ingelheim Pharmaceuticals, Inc.
- 0597-0044 - Micardis Hct
- 0597-0044-37 - 3 BLISTER PACK in 1 CARTON / 10 TABLET in 1 BLISTER PACK
- 0597-0044 - Micardis Hct
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0597-0044-37 identifies a specific commercial package of 3 blister pack in 1 carton / 10 tablet in 1 blister pack of Micardis Hct, a human prescription drug labeled by Boehringer Ingelheim Pharmaceuticals, Inc.. This tablet is formulated for oral use and contains hydrochlorothiazide; telmisartan as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Boehringer Ingelheim Pharmaceuticals, Inc. on December 01, 2000. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. This product contains 2 medications: telmisartan and hydrochlorothiazide. Telmisartan belongs to a class of drugs called angiotensin receptor blockers (ARBs). It works by relaxing blood vessels so blood can flow more easily. Hydrochlorothiazide is a "water pill" (diuretic). It increases the amount of urine you make, especially when you first start the medication. It also helps to relax the blood vessels so that blood can flow more easily. These medications are used together when 1 drug alone is not controlling your blood pressure. Your doctor may direct you to start taking the individual medications first, and then switch you over to this combination product if this is the best dose combination for you.
How is this Boehringer Ingelheim Pharmaceuticals, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00597004437. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 3 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.